Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ágnes Benedict

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 22, 2024
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio ModelÁgnes Benedict, Gábor Szabó, Kinga Marczell, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision MakingTing-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Expert Review of Hematology|October 14, 2017
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United StatesAndrzej J Jakubowiak, Ivan Houisse, István Májer, et al.
Journal of Medical Economics|May 26, 2016
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspectiveAndrzej J Jakubowiak, Marco Campioni, Ágnes Benedict, et al.
Pharmacoeconomics|June 6, 2022
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 DiabetesÁgnes Benedict, Emily R Hankosky, Kinga Marczell, et al.
Future Oncology (London, England)|August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in ScotlandSimone Critchlow, Ash Bullement, Simon Crabb, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of the National Comprehensive Cancer Network : JNCCN|April 22, 2024
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio ModelÁgnes Benedict, Gábor Szabó, Kinga Marczell, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision MakingTing-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Expert Review of Hematology|October 14, 2017
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United StatesAndrzej J Jakubowiak, Ivan Houisse, István Májer, et al.
Journal of Medical Economics|May 26, 2016
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspectiveAndrzej J Jakubowiak, Marco Campioni, Ágnes Benedict, et al.
Pharmacoeconomics|June 6, 2022
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 DiabetesÁgnes Benedict, Emily R Hankosky, Kinga Marczell, et al.
Future Oncology (London, England)|August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in ScotlandSimone Critchlow, Ash Bullement, Simon Crabb, et al.
Pageof 1